Successful penicillin allergy de-labelling
29th EAHP Congress highlights Approximately 10% of inpatients are labelled as ‘allergic to penicillin’ but the vast majority have not experienced a true allergic reaction. Having a penicillin… read more.
29th EAHP Congress highlights Approximately 10% of inpatients are labelled as ‘allergic to penicillin’ but the vast majority have not experienced a true allergic reaction. Having a penicillin… read more.
Merck known as MSD outside of the United States and Canada, announced that new clinical and outcomes research data will be presented at the American College of Cardiology’s… read more.
Pfizer Inc. announced positive topline results from the progression-free survival (PFS) analysis of the Phase III BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (Erbitux) and mFOLFOX6… read more.
Regeneron Pharmaceuticals, Inc. announced positive results from the Phase III C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically significant and… read more.
29th EAHP Congress highlights Biopharmaceuticals are complex biological molecules that require careful storage and handling to ensure medication integrity. They are especially sensitive to mechanical stress and shaking,… read more.
Jazz Pharmaceuticals plc announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Calquence…. read more.
Merck known as MSD outside of the United States and Canada, announced that new clinical and outcomes research data will be presented at the American College of Cardiology’s… read more.
NICE (UK): Selpercatinib is recommended as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults,… read more.
Cidara Therapeutics, Inc, a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies, announced two upcoming presentations at the 38th International Conference on Antiviral… read more.
The FDA has approved Merilog (insulin-aspart-szjj) as biosimilar to NovoLog (insulin aspart) from Sanofi for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus…. read more.
Cytokinetics, Incorporated announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic cardiomyopathy (HCM), at the American College of Cardiology (ACC) Annual Scientific Session &… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.